Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment?

American Journal of Hematology · Published 2026-08-03 · DOI 10.1002/ajh.70466

Free full text

Authors (1)

Martin H. Steinberg

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Steinberg, M. (2026). Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment?. American Journal of Hematology. https://doi.org/10.1002/ajh.70466

Related articles

• Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management · American Journal of Hematology · 2026 · Same journal
• Treatment Patterns and Clinical Outcomes After Immunotherapy Failure in Patients With Natural Killer/T‐Cell Lymphoma · American Journal of Hematology · 2026 · Same journal
• Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia · American Journal of Hematology · 2026 · Same journal
• Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”? · American Journal of Hematology · 2026 · Same journal
• ICC / WHO ‐Defined and NGS ‐Annotated Idiopathic Hypereosinophilia ( iHES / iHE ): Mutations, Clinical and Treatment Details, and Predictors of Survival · American Journal of Hematology · 2026 · Same journal
• Promoter TERT ‐ Related Hematopoietic Somatic Mosaicism in Patients With Telomere Biology Disorders · American Journal of Hematology · 2026 · Same journal
• Mosaic Chromosomal Alterations Identify Ultra‐High Risk Clonal Hematopoiesis in Patients With Lymphoma Undergoing Intensive Chemotherapy · American Journal of Hematology · 2026 · Same journal
• A New Fetal Hemoglobin‐Related Phenotype in Sickle Cell Anemia · American Journal of Hematology · 2026 · Same journal
• p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53 ‐Mutated Cases · American Journal of Hematology · 2026 · Same journal
• Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma · American Journal of Hematology · 2026 · Same journal